Comparison of inflammatory markers in type 2 diabetic patients treated with empagliflozin, metformin, and sulfonylurea

Pegah Mohaghegh ¹ * , Mohammad Reza Rezvanfar ² , Farideh Jalali-Mashayekhi ³ , Zahra Amerei ⁴ , Mohammad Hosseinzadeh ³

Chairperson:

Prof. Morteza Hashemzadeh Chaleshtori

Editor in Chief:

Prof. Esfandiar Heidarian

Indexing & abstracting

Follower of

COPE